Skip to main content

Novocure Limited (NVCR)

NASDAQ: NVCR · IEX Real-Time Price · USD
127.30 -3.70 (-2.82%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap13.19B
Revenue (ttm)544.83M
Net Income (ttm)-4.57M
Shares Out103.65M
EPS (ttm)-0.05
PE Ration/a
Forward PE909.09
Dividendn/a
Ex-Dividend Daten/a
Volume277,542
Open130.74
Previous Close131.00
Day's Range126.86 - 131.00
52-Week Range103.00 - 232.76
Beta1.10
AnalystsHold
Price Target177.14 (+39.2%)
Est. Earnings DateOct 28, 2021

About NVCR

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and int...

IndustryHealth Care Equipment & Supplies
IPO DateOct 2, 2015
CEOAsaf Danziger
Employees1,023
Stock ExchangeNASDAQ
Ticker SymbolNVCR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for Novocure stock is "Hold." The 12-month stock price forecast is 177.14, which is an increase of 39.15% from the latest price.

Price Target
$177.14
(39.15% upside)
Analyst Consensus: Hold

News

Novocure To Test Its Tumor Treating Fields With Roche's Tecentriq In Pancreatic Cancer

Novocure Ltd (NASDAQ: NVCR) has entered into a clinical trial collaboration agreement with Roche Holdings AG (OTC: RHHBY) to develop Tumor Treating Fields (TTFields) together with Roche's atezolizumab i...

1 week ago - Benzinga

Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combi...

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR #pancreaticcancer--Novocure has entered into a clinical trial collaboration with Roche to evaluate TTFields as part of a novel combination to treat pancreat...

1 week ago - Business Wire

This Promising Healthcare Stock Is Down 50% From Its Highs; Should You Buy the Dip?

Novocure has been fantastic for investors, up over 1,600% in the past five years. But in the past six months, shareholders have been on a roller coaster.

2 weeks ago - The Motley Fool

FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System for Advanced Liver Cancer

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--The U.S. FDA has granted breakthrough device designation to Novocure's NovoTTF-200T™ System for advanced liver cancer.

2 weeks ago - Business Wire

Novocure to Participate in the 2021 Wells Fargo Virtual Healthcare Conference

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure will participate in the 2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021.

3 weeks ago - Business Wire

Novocure Appoints Bill Burke as Chief Human Resources Officer

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure announced that William (Bill) Burke has been promoted to Chief Human Resources Officer, effective September 1, 2021.

3 weeks ago - Business Wire

What's Next for Novocure?

The company has several key data readouts on the way.

1 month ago - The Motley Fool

Here's Why Novocure Dipped 19% This Week

Uptake of the company's revolutionary disease-controlling device isn't progressing as quickly as expected.

1 month ago - The Motley Fool

Why Novocure Tanked on Thursday

Investors are seeing red in the company's latest earnings report.

1 month ago - The Motley Fool

NovoCure (NVCR) Reports Q2 Loss, Misses Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of -800.00% and -5.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Novocure Stock Dips As Q2 Earnings Trail Estimates; Higher Costs Hit Bottom Line

Novocure Ltd (NASDAQ: NVCR) posted a net loss of $14.6 million in Q2, compared to a net income of $1.7 million a year ago. EPS came in at $(0.14), missing the consensus of $0.01 Q2 net revenues were $13...

1 month ago - Benzinga

NovoCure: Q2 Earnings Insights

Shares of NovoCure (NASDAQ:NVCR) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share were down 800.00% over the past year to ($0.14), which missed the estimat...

1 month ago - Benzinga

Novocure Reports Second Quarter 2021 Financial Results and Provides Company Update

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR #earnings--Novocure reported financial results for the second quarter 2021, highlighting commercial strength and strategic investment.

1 month ago - Business Wire

NovoCure (NVCR) Q2 Earnings Preview: What's in the Cards?

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Novocure Announces Recipients of 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure today announced the recipients of the 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research program.

2 months ago - Business Wire

Novocure to Report Second Quarter 2021 Financial Results

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure announced today that it will report financial results for the second quarter 2021 on July 29, 2021, before the U.S. financial markets open.

2 months ago - Business Wire

Oncology Space Gains Momentum in 2021: 5 Stocks to Focus on

Oncology stocks like OncoCyte (OCX), PerkinElmer (PKI), Catalent (CTLT), Cardiff Oncology (CRDF) and NovoCure (NVCR) are expected to continue their run over the next few months.

Other symbols:CRDFCTLTNVSOCXPKI
2 months ago - Zacks Investment Research

Why Did Novocure Shares Plunge Today?

Novocure Ltd (NASDAQ: NVCR) has announced final results from its phase 2 pilot HEPANOVA trial evaluating Tumor Treating Fields (TTFields) together with Bayer AG's (OTC: BAYRY) Nexavar (sorafenib) for he...

2 months ago - Benzinga

Why Novocure Stock Is Sliding Today

Investors hoped for better results from the company's phase 2 study.

2 months ago - The Motley Fool

Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer

ST. HELIER, Jersey--(BUSINESS WIRE)-- #patientforward--Novocure announced final safety and efficacy results from its HEPANOVA trial in liver cancer, and plans to proceed with a phase 3 pivotal trial.

2 months ago - Business Wire

Up 1,100%, This Cancer-Fighting Stock Has Room To Run

NovoCure's unique treatment for cancerous tumors is both a medical breakthrough and an investment opportunity.

2 months ago - The Motley Fool

4 Toxic Stocks That May Disrupt Your Peace & Portfolio

Investors who can pinpoint the overhyped toxic stocks and discard them at the right time are the ones who are poised to benefit.

Other symbols:JDMANUPLTR
2 months ago - Zacks Investment Research

Novocure Initiates Usability Study for Flexible Torso Array

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure announced it has advanced a new, flexible torso array into a clinical usability study.

3 months ago - Business Wire

3 Unstoppable Stocks That Can Leave Dogecoin in the Dust

These fundamentally strong stocks are much better bets than the over-hyped Dogecoin.

Other symbols:LMNDPYPL
3 months ago - The Motley Fool

2 Innovative Growth Stocks to Buy for June

Got cash? Consider these high-flying growth stocks.

Other symbols:RBLX
3 months ago - The Motley Fool